Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2

The associate DOI for this manuscript is: https://doi.org/10.1186/s12967-021-03208-3
Published in 2022 by Lucia Lopalco et al.
Twenty-six naïve and 9 previously SARS-CoV-2 infected subjects during the second wave of the pandemic
in Italy were enrolled for this study. The two groups had comparable demographic and clinical characteristics. By
means of ELISA and pseudotyped-neutralization assays, we investigated the kinetics of developed IgG-RBD and their
neutralizing activity against both the ancestral D614G and the SARS-CoV-2 variants of concern emerged later, respectively.
Although after 15 weeks from vaccination IgG-RBD dropped in all participants, naïve subjects experienced
a more dramatic decline than those with previous SARS-CoV-2 infection. Neutralizing antibodies remained higher in
subjects with SARS-CoV-2 history and conferred broad-spectrum protection.
A table including all clinical data, ELISA and Neutralization assay is attached here (named Vaccinated + Neut + ELISA)

本手稿关联的DOI为：https://doi.org/10.1186/s12967-021-03208-3。该研究由Lucia Lopalco等人于2022年发表。在意大利疫情第二波期间，招募了26名初次感染和9名既往感染SARS-CoV-2的受试者参与本研究。两组受试者在人口统计学和临床特征方面具有可比性。通过酶联免疫吸附测定（ELISA）和伪型中和试验，本研究探讨了形成的IgG-RBD的动态变化及其对祖先D614G和随后出现的SARS-CoV-2关注变异株的中和活性。尽管在疫苗接种后15周，所有受试者的IgG-RBD水平均有所下降，但初次感染受试者的下降幅度显著大于既往感染SARS-CoV-2的受试者。具有SARS-CoV-2感染史的受试者的中和抗体水平保持较高，并提供了广泛的保护作用。包含所有临床数据、ELISA和中和试验结果的相关表格已附于其后（命名为“接种疫苗 + 中和 + ELISA”）。